Our 9th Annual Huntington Disease Research Symposium was another success!
With special thanks to Lundbeck, Inc. we were able to host about 120 guests for two sessions of informative talks on the latest advances in laboratory and clinical Huntington disease (HD) research. Read more
Plaques made of amyloid protein are a defining feature of Alzheimer’s disease (AD) but are not typically seen in frontotemporal dementia (FTD). Unfortunately these plaques have not been able to be definitively identified until after the death of a patient, when tissue collected during an autopsy is analyzed with a microscope. Scientists have been searching for a disease marker that can be seen in living people for both accurate diagnosis and tracking the effectiveness of potential therapies. New research shows a marker developed to detect plaque in the brain may help doctors make a more accurate diagnosis between Alzheimer’s and FTD. Read more
Rumors started buzzing about five years ago when six different groups of scientists began narrowing in on a region of chromosome 9 to explain what they were seeing in the clinic. Frontotemporal dementia (FTD), a behavioral and cognitive neurodegenerative disease, and amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), a neuromuscular degenerative disease, often run in the same family and may even appear in the same person. Narrowing down the right chromosome was a start, but chromosome 9 has 1534 genes on it. How do you find the right one? Read more